Johnson & Johnson could face generic competition for its blockbuster prostate cancer therapy Zytiga (abiraterone acetate) as early as October now that the composition and method of use patent covering the drug has been found unpatentable by the US Patent and Trademark Office's Patent Trial and Appeal Board.
On Jan. 17, the Board issued final written decisions in five inter partes review (IPR) cases challenging patent No. 8,822,438,...








